Contact this trialFirst, we need to learn more about you.
Complement Inhibitor
BCX9930 for Paroxysmal Nocturnal Hemoglobinuria
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial will compare the new drug BCX9930 to the current standard of care for PNH, which is a C5 inhibitor. The trial will measure how well the drugs treat PNH and how safe they are.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.